Antitrust mistake enters the drug market

Antitrust mistake enters the drug market

Lawmakers on both the left and right are increasingly blaming pharmacy benefit managers (PBMs) — the intermediaries that negotiate prescription drug prices between manufacturers, insurers, and pharmacies — for rising healthcare costs. Last month, a bipartisan group of legislators reintroduced the Patients Before Monopolies Act, which would prohibit companies that own PBMs from also owning […]

Original Source

Read the full article at Washingtonexaminer →

KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.